Low back pain has ranked first among causes of disability for the last three decades. Back pain, however, is not inevitable, even if that sometimes feels like the case.
More than six years after he finished serving eight months of a two-year prison sentence, Dr. Darryl Jordan Gebien wants to talk about his experience, in hopes of helping other people with addictions.
At the heart of Novo Nordisk’s acquisition of Montreal-based Inversago Pharma is an oral agonist designed to block the receptor protein CB1, which plays an important role in metabolism and appetite regulation.